Articles citing this paper

Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines

Vincent J. Cornelisse

^A ^B ^C ^* , John J. M. Kearley ^A , Jose Vargas Castillo ^A , Lindsay Macharg ^D , Virginia A. McLaughlin ^E , Susan J. Jack ^E and Caitlin Swift ^F

+ Author Affiliations

- Author Affiliations

^A Kirketon Road Centre, NSW Health, Sydney, NSW, Australia.

^B The Kirby Institute, University of NSW, Sydney, NSW, Australia.

^C Monash University, Melbourne, Vic., Australia.

^D Queenstown Medical Centre, Queenstown, Aotearoa, New Zealand.

^E Te Whatu Ora Southern, National Public Health Service, Aotearoa, New Zealand.

^F Public Health Unit, South Eastern Sydney Local Health District, Sydney, NSW, Australia.

^* Correspondence to: Vincent.Cornelisse1@monash.edu

Handling Editor: Darren Russell

Sexual Health 20(6) 585-587 https://doi.org/10.1071/SH23139
Submitted: 28 July 2023 Accepted: 25 September 2023 Published: 19 October 2023

1 articles found in Crossref database.

Breakthrough infection and reinfection in patients with mpox

Jiang Wenyi, Hu Yibo, Yang Xiu, Hou Lingli, Zhang Jingjing, Niu Hong, Hu Congxia, Lin Jihui

Reviews in Medical Virology. 2024 34(2).

[Crossref]